134 related articles for article (PubMed ID: 16472704)
21. Targeted therapy for nonsmall cell lung cancer: focusing on angiogenesis, the epidermal growth factor receptor and multikinase inhibitors.
Kotteas EA; Charpidou AG; Syrigos KN
Anticancer Drugs; 2010 Feb; 21(2):151-68. PubMed ID: 20016368
[TBL] [Abstract][Full Text] [Related]
22. Emerging role of rexinoids in non-small cell lung cancer: focus on bexarotene.
Rigas JR; Dragnev KH
Oncologist; 2005 Jan; 10(1):22-33. PubMed ID: 15632250
[TBL] [Abstract][Full Text] [Related]
23. Role of targeted therapy in non-small cell lung cancer: hype or hope?
Langer CJ
Expert Rev Anticancer Ther; 2003 Aug; 3(4):443-55. PubMed ID: 12934657
[TBL] [Abstract][Full Text] [Related]
24. The biology of non-small-cell lung cancer: identifying new targets for rational therapy.
Rosell R; Felip E; Garcia-Campelo R; Balaña C
Lung Cancer; 2004 Nov; 46(2):135-48. PubMed ID: 15474661
[TBL] [Abstract][Full Text] [Related]
25. Targeting the HER1/EGFR receptor to improve outcomes in non-small-cell lung cancer.
Gatzemeier U
Oncology (Williston Park); 2003 Nov; 17(11 Suppl 12):7-10. PubMed ID: 14682117
[TBL] [Abstract][Full Text] [Related]
26. Targeted therapies and non-small-cell lung cancer: work in progress?
Gridelli C
Curr Opin Oncol; 2006 Mar; 18(2):132-4. PubMed ID: 16462181
[No Abstract] [Full Text] [Related]
27. New biological agents in the treatment of advanced non-small cell lung cancer.
Morrow PK; Kim ES
Semin Respir Crit Care Med; 2005 Jun; 26(3):323-32. PubMed ID: 16052434
[TBL] [Abstract][Full Text] [Related]
28. Novel therapies in non-small cell lung cancer.
Zaba O; Grohe C; Merk J
Minerva Chir; 2011 Jun; 66(3):235-44. PubMed ID: 21666560
[TBL] [Abstract][Full Text] [Related]
29. [New strategies for NSCLC: is inhibition of tumour vasculature useful].
Reinmuth N; Steins M; Kreuter M; Thomas M
Pneumologie; 2010 Jun; 64(6):376-86. PubMed ID: 20229453
[TBL] [Abstract][Full Text] [Related]
30. Targeting angiogenesis in lung cancer.
Sandler AB
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S16-22. PubMed ID: 16459175
[TBL] [Abstract][Full Text] [Related]
31. [Development of molecular targeting drugs for the treatment of cancer-therapeutic potential and issues to be addressed in global development].
Akaza H; Aiba K; Isonishi S; Ogawa O; Shibuya M; Sone S; Tsuruo T; Noguchi S; Hinotsu S; Kono S; Mikami O; Blackledge G; Vose B; Stribling D
Gan To Kagaku Ryoho; 2000 Oct; 27(11):1681-93. PubMed ID: 11057319
[TBL] [Abstract][Full Text] [Related]
32. Second-line therapy for non-small-cell lung cancer.
Arango BA; Castrellon AB; Santos ES; Raez LE
Clin Lung Cancer; 2009 Mar; 10(2):91-8. PubMed ID: 19362951
[TBL] [Abstract][Full Text] [Related]
33. The need for third-line treatment in non-small cell lung cancer: an overview of new options.
Syrigos KN; Saif MW; Karapanagiotou EM; Oikonomopoulos G; De Marinis F
Anticancer Res; 2011 Feb; 31(2):649-59. PubMed ID: 21378351
[TBL] [Abstract][Full Text] [Related]
34. Development of new first-line therapeutic options for non-small-cell lung cancer.
Crinò L; Foglietta J; Hamzaj A
Lung Cancer; 2006 Dec; 54 Suppl 2():S19-24. PubMed ID: 17056151
[TBL] [Abstract][Full Text] [Related]
35. Milestones in the use of chemotherapy for the management of non-small cell lung cancer (NSCLC).
Klastersky J; Awada A
Crit Rev Oncol Hematol; 2012 Jan; 81(1):49-57. PubMed ID: 21396829
[TBL] [Abstract][Full Text] [Related]
36. Molecular targeted therapy for early-stage non-small-cell lung cancer: will it increase the cure rate?
Martinez P; Martinez-Marti A; Navarro A; Cedrés S; Felip E
Lung Cancer; 2014 May; 84(2):97-100. PubMed ID: 24582269
[TBL] [Abstract][Full Text] [Related]
37. Advanced NSCLC: from cytotoxic systemic chemotherapy to molecularly targeted therapy.
Hoang T; Schiller JH
Expert Rev Anticancer Ther; 2002 Aug; 2(4):393-401. PubMed ID: 12647982
[TBL] [Abstract][Full Text] [Related]
38. Rationale for investigation of epidermal growth factor receptor inhibitors in definitive treatment of locally advanced non-small cell lung cancer and head and neck cancer.
Choy H; Kim DW
Semin Respir Crit Care Med; 2004; 25 Suppl 1():33-43. PubMed ID: 16088519
[TBL] [Abstract][Full Text] [Related]
39. Second- and third-line treatments in non-small cell lung cancer.
Kumar A; Wakelee H
Curr Treat Options Oncol; 2006 Jan; 7(1):37-49. PubMed ID: 16343367
[TBL] [Abstract][Full Text] [Related]
40. Future directions in the second-line treatment of non-small cell lung cancer.
Rosell R; Cecere F; Cognetti F; Cuello M; Sanchez JM; Taron M; Reguart N; Jablons D
Semin Oncol; 2006 Feb; 33(1 Suppl 1):S45-51. PubMed ID: 16472709
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
